American Society of Clinical Oncology

SHERPA: White

People

  1. Kris
    Kris
  2. Miller
    Miller
  3. Heelan
    Heelan
  4. Dunne
    Dunne
  5. Riely
    Riely
  6. Drilon
    Drilon
  7. Ginsberg
    Ginsberg
  8. Janjigian
    Janjigian
  9. Ng
    Ng
  10. Rusch
    Rusch

Groups

  1. Department of Medicine (11)
  2. Solid Tumor Oncology Division (11)
  3. Thoracic Oncology (11)
  4. Nursing (7)
  5. Advanced Practice Providers (4)
  6. Survivorship Research (3)
  7. Center for Pancreatic Cancer Research (2)
  8. Gastrointestinal Oncology Service (2)
  9. Biostatistics Service (1)
  10. Body Imaging Service (1)
Search Within
  1. "Vincent Miller"
  2. "Lee Krug"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
Groups
  1. Department of Medicine (11)
  2. Solid Tumor Oncology Division (11)
  3. Thoracic Oncology (11)
  4. Nursing (7)
  5. Advanced Practice Providers (4)
  6. Survivorship Research (3)

More Groups

People
  1. Lee Krug (11)
  2. Mark Kris (11)
  3. Vincent Miller (11)
  4. Christopher Azzoli (8)
  5. Naiyer Rizvi (8)
  6. Barbara Pizzo (5)

More People

Years
  1. 2012 (1)
  2. 2010 (1)
  3. 2008 (1)
  4. 2007 (1)
  5. 2005 (2)
  6. 2004 (3)

More Years

Publications
  1. Journal of Clinical Oncology (11)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Drilon, A. E. D.; Varghese, A. M.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Meeting Abstract

    Riely, G. J.; Janjigian, Y. Y.; Azzoli, C. G.; Pietanza, M.; Krug, L. M.; Rizvi, N. A.; Kris, M. G.; Miller, V. A.; Pao, W.; Ginsberg, M. S.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2
    Meeting Abstract

    Rizvi, N. A.; Kris, M. G.; Miller, V. A.; Krug, L. M.; Bekele, S.; Dowlati, A.; Rowland, K. M.; Salgia, R.; Aggarwal, N.; Gadgeel, S. M.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase I study of the antifolate pralatrexate given with vitamin B(12) and folic acid supplementation in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Azzoli, C. G.; Krug, L.; Miller, V.; Bekele, S.; Tyson, L.; Dunne, M.; Huntington, M.; Saunders, M.; Kris, M. G.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Milton, D. T.; Kris, M. G.; Azzoli, C. G.; Gomez, J. E.; Heelan, R.; Krug, L. M.; Pao, W.; Pizzo, B.; Rizvi, N. A.; Miller, V. A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Measurements of total DNA and methylated tumor suppressor genes in the plasma of patients with metastatic non-small cell lung cancer (NSCLC) before, and after chemotherapy, as potential biomarkers for response to treatment
    Meeting Abstract

    Azzoli, C. G.; Park, S.; Gomez, J.; Krug, L.; Miller, V.; Rizvi, N.; Ben-Porat, L.; Danenberg, K.; Danenberg, P.; Kris, M.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study
    Meeting Abstract

    Milton, D. T.; Miller, V. A.; Azzoli, C. G.; Dunne, M.; Gomez, J. E.; Heelan, R.; Krug, L. M.; Ramies, D.; Rizvi, N. A.; Kris, M. G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • C-kit protein expression in tumor specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer (SCLC): A phase II clinical trial
    Meeting Abstract

    Krug, L. M.; Crapanzano, J. P.; Miller, V. A.; Azzoli, C. G.; Rizvi, N.; Gomez, J.; Pizzo, B.; Tyson, L.; Dunne, M.; Kris, M. G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Journal Article

    Miller, V. A.; Kris, M. G.; Shah, N.; Patel, J.; Azzoli, C.; Gomez, J.; Krug, L. M.; Pao, W.; Rizvi, N.; Pizzo, B.; more...
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
    Journal Article

    Miller, V. A.; Johnson, D. H.; Krug, L. M.; Pizzo, B.; Tyson, L.; Perez, W.; Krozely, P.; Sandler, A.; Carbone, D.; Heelan, R. T.; more...
    Journal of Clinical Oncology (2003)

    Fulltext@MSK | Save